Reported Oct 25, 2023 · Terminated

Moxifloxacin in Balanced Salt Solution, Solution for Intraocular Injection, 600 mcg/0.4mL (150 mcg/0.1mL) Syringe, Rx…

Pine Pharmaceuticals, LLC

Moderate riskThis product could cause temporary or reversible health problems — stop using it.

What you should do

Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.

Firm contact: Pine Pharmaceuticals, LLC · 355 Riverwalk Pkwy · Tonawanda, NY · 14150-5837

Is this the product you have?

  • Moxifloxacin in Balanced Salt Solution, Solution for Intraocular Injection, 600 mcg/0.4mL (150 mcg/0.1mL) Syringe, Rx only
  • Compounded by
    • Pine Pharmaceuticals 355 Riverwalk Parkway
    • Tonawanda
    • NY 14150
Lot codes and dates
    • Lot #: 67480
    • Exp. Date 10/9/2023
    • 68640
    • Exp. Date 12/3/2023
    • 68769
    • Exp. Date 12/9/2023
    • 68760
    • Exp. Date 12/10/2023
    • 68925
    • Exp. Date 12/16/2023
    • 70119
    • Exp. Date 1/20/2024
Amount recalled
2484 syringes

This recall covers 16 products

The agency filed one notice per product. You are reading one of them; the other 15 are below.

3 more are in the archive.

Where it was sold

  • Nationwide

Why it was recalled

Lack of Assurance of Sterility

This product could cause temporary or reversible health problems — stop using it.

Want the full recall guide?

The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.

Free recall alerts

Get alerted about new Pine Pharmaceuticals, LLC recalls

One email when a matching recall is published. No account, no cost, unsubscribe in one click.

Where this came from

Source: U.S. Food & Drug Administration (openFDA)

Read the FDA (openFDA drug enforcement) notice

Notice updated May 15, 2024 · Data as of Sep 19, 5:07 PM UTC

RecallNow is not a government agency. Every fact on this page is published by the FDA, USDA or CPSC and links back to their notice.